In summary, this study provides both clinical and mechanistic evidence supporting the functional role of the CBX7/USP44/c-MYC/LDHA axis in regulating meningioma progression through reprogramming glucose metabolism from glycolysis to OXPHOS, shedding light on a previously unexpected role of CBX7 in meningioma progression and a potential therapeutic strategy for high-grade meningioma patients. This evidence concerns the gene MYC and meningioma.